Reducing antibiotic treatment duration for ventilator-associated pneumonia (REGARD-VAP): a trial protocol for a randomised clinical trial

Yin Mo, Timothy Eoin West, Graeme MacLaren, Suchart Booraphun, Andrew Yunkai Li, Gyan Kayastha, Yie Hui Lau, Yin Tze Chew, Ploenchan Chetchotisakd, Paul Anantharajah Tambyah, Direk Limmathurotsakul, Ben Cooper, Yin Mo, Timothy Eoin West, Graeme MacLaren, Suchart Booraphun, Andrew Yunkai Li, Gyan Kayastha, Yie Hui Lau, Yin Tze Chew, Ploenchan Chetchotisakd, Paul Anantharajah Tambyah, Direk Limmathurotsakul, Ben Cooper

Abstract

Introduction: Ventilator-associated pneumonia (VAP) is the most common nosocomial infection in intensive care units (ICUs). Using short-course antibiotics to treat VAP caused by Gram-negative non-fermenting bacteria has been reported to be associated with excess pneumonia recurrences. The "REducinG Antibiotic tReatment Duration for Ventilator-Associated Pneumonia" (REGARD-VAP) trial aims to provide evidence for using a set of reproducible clinical criteria to shorten antibiotic duration for individualised treatment duration of VAP.

Methods and analysis: This is a randomised controlled hierarchical non-inferiority-superiority trial being conducted in ICUs across Nepal, Thailand and Singapore. The primary outcome is a composite endpoint of death and pneumonia recurrence at day 60. Secondary outcomes include ventilator-associated events, multidrug-resistant organism infection or colonisation, total duration of antibiotic exposure, mechanical ventilation and hospitalisation. Adult patients who satisfy the US Centers for Disease Control and Prevention National Healthcare Safety Network VAP diagnostic criteria are enrolled. Participants are assessed daily until fever subsides for >48 hours and have stable blood pressure, then randomised to a short duration treatment strategy or a standard-of-care duration arm. Antibiotics may be stopped as early as day 3 if respiratory cultures are negative, and day 5 if respiratory cultures are positive in the short-course arm. Participants receiving standard-of-care will receive antibiotics for at least 8 days. Study participants are followed for 60 days after enrolment. An estimated 460 patients will be required to achieve 80% power to determine non-inferiority with a margin of 12%. All outcomes are compared by absolute risk differences. The conclusion of non-inferiority, and subsequently superiority, will be based on unadjusted and adjusted analyses in both the intention-to-treat and per-protocol populations.

Ethics and dissemination: The study has received approvals from the Oxford Tropical Research Ethics Committee and the respective study sites. Results will be disseminated to patients, their caregivers, physicians, the funders, the critical care societies and other researchers.

Trial registration number: NCT03382548.

Keywords: infectious diseases; intensive & critical care; statistics & research methods.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Figures

Figure 1
Figure 1
Study treatment protocol flow diagram.

References

    1. Vincent J-L, et al. . International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323. 10.1001/jama.2009.1754
    1. Kalil AC, Metersky ML, Klompas M, et al. . Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases Society of America and the American thoracic Society. Clin Infect Dis [Internet] 2016;63:e61–111. 10.1093/cid/ciw353
    1. Stebbings AE, Ti TY, Tan WC. Hospital acquired pneumonia in the medical intensive care unit--a prospective study. Singapore Med J 1999;40:508–12.
    1. Arabi Y, Al-Shirawi N, Memish Z, et al. . Ventilator-Associated pneumonia in adults in developing countries: a systematic review. Int J Infect Dis 2008;12:505–12. 10.1016/j.ijid.2008.02.010
    1. Fabregas N, Ewig S, Torres A, et al. . Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsies. Thorax 1999;54:867–73. 10.1136/thx.54.10.867
    1. Hill JD, Ratliff JL, Parrott JC, et al. . Pulmonary pathology in acute respiratory insufficiency: lung biopsy as a diagnostic tool. J Thorac Cardiovasc Surg 1976;71:64–71. 10.1016/S0022-5223(19)40261-4
    1. Chastre J, Wolff M, Fagon J-Y, et al. . Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA 2003;290:2588. 10.1001/jama.290.19.2588
    1. Capellier G, Mockly H, Charpentier C, et al. . Early-Onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment. PLoS One 2012;7:e41290. 10.1371/journal.pone.0041290
    1. Singh N, Rogers P, Atwood CW, et al. . Short-Course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. Am J Respir Crit Care Med 2000;162:505–11. 10.1164/ajrccm.162.2.9909095
    1. Micek ST, Ward S, Fraser VJ, et al. . A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004;125:1791–9. 10.1378/chest.125.5.1791
    1. Brun-Buisson C, Fartoukh M, Lechapt E, et al. . Contribution of blinded, protected quantitative specimens to the diagnostic and therapeutic management of ventilator-associated pneumonia. Chest 2005;128:533–44. 10.1378/chest.128.2.533
    1. Raman K, Nailor MD, Nicolau DP, et al. . Early antibiotic discontinuation in patients with clinically suspected ventilator-associated pneumonia and negative quantitative bronchoscopy cultures. Crit Care Med 2013;41:1656–63. 10.1097/CCM.0b013e318287f713
    1. Jones RN. Microbial etiologies of Hospital‐Acquired bacterial pneumonia and Ventilator‐Associated bacterial pneumonia. Clin Infect Dis 2010;51:S81–7. 10.1086/653053
    1. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, et al. . Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by gram-negative bacteria. J Antimicrob Chemother 2010;65:2645–9. 10.1093/jac/dkq360
    1. Inchai J, Pothirat C, Liwsrisakun C, et al. . Ventilator-Associated pneumonia: epidemiology and prognostic indicators of 30-day mortality. Jpn J Infect Dis 2015;68:181–6. 10.7883/yoken.JJID.2014.282
    1. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. . Spirit 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. 10.1136/bmj.e7586
    1. Piaggio G, Elbourne DR, Pocock SJ, et al. . Reporting of Noninferiority and equivalence randomized trials. JAMA 2012;308:2594. 10.1001/jama.2012.87802
    1. U.S Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) . Pneumonia (Ventilator-associated [VAP] and non-ventilator-associated Pneumonia [PNEU]) Event, 2018. Available:
    1. Fàbregas N, Ewig S, Torres A, et al. . Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsies. Thorax 1999;54:867–73. 10.1136/thx.54.10.867
    1. Jones AE, Trzeciak S, Kline JA. The sequential organ failure assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. Crit Care Med 2009;37:1649–54. 10.1097/CCM.0b013e31819def97
    1. The Canadian Critical Care Trials Group . A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006;355:2619–30. 10.1056/NEJMoa052904
    1. Berton DC, Kalil AC, Teixeira PJZ. Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. Cochrane Database Syst Rev 2014;10:CD006482. 10.1002/14651858.CD006482.pub4
    1. European Society of Clinical Microbiology and Infectious Diseases . The European Committee on antimicrobial susceptibility testing. routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST. version 8.0, 2018. Available:
    1. CLSI . M100: antimicrobial susceptibility testing standards, 2019. Available:
    1. U.S. Department of Health and Human Services, Food and Drug Administration, buckmans . Non-Inferiority clinical trials to establish effectiveness guidance for industry, 2016. Available:
    1. Mo Y, Lim C, Mukaka M, et al. . Statistical considerations in the design and analysis of non-inferiority trials with binary endpoints in the presence of non-adherence: a simulation study. Wellcome Open Res 2019;4:207. 10.12688/wellcomeopenres.15636.1
    1. Mo Y, Lim C, Watson JA, et al. . Non-adherence in non-inferiority trials: pitfalls and recommendations. BMJ 2020;370:m2215. 10.1136/bmj.m2215
    1. Bekaert M, Timsit J-F, Vansteelandt S, et al. . Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med 2011;184:1133–9. 10.1164/rccm.201105-0867OC
    1. Mansournia MA, Altman DG. Inverse probability weighting. BMJ 2016;352:i189. 10.1136/bmj.i189
    1. Hernán M, Robins J. Causal inference: what if. Boca Raton: Chapman & Hall/CRC, 2020.
    1. Matilde Sanchez M, Chen X. Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat. Stat Med 2006;25:1169–81. 10.1002/sim.2244
    1. Combes A, Figliolini C, Trouillet J-L, et al. . Factors predicting ventilator-associated pneumonia recurrence. Crit Care Med 2003;31:1102–7. 10.1097/01.CCM.0000059313.31477.2C
    1. Combes A, Luyt C-E, Fagon J-Y, et al. . Early predictors for infection recurrence and death in patients with ventilator-associated pneumonia. Crit Care Med 2007;35:146–54. 10.1097/01.CCM.0000249826.81273.E4
    1. Zahar J-R, Clec'h C, Tafflet M, et al. . Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? Clin Infect Dis 2005;41:1224–31. 10.1086/496923
    1. Wahl WL, Franklin GA, Brandt M-M, et al. . Does bronchoalveolar lavage enhance our ability to treat ventilator-associated pneumonia in a trauma-burn intensive care unit? J Trauma 2003;54:633–9. 10.1097/01.TA.0000057229.70607.F2
    1. Stéphan F, Mabrouk N, Decailliot F, et al. . Ventilator-Associated pneumonia leading to acute lung injury after trauma: importance of Haemophilus influenzae. Anesthesiology 2006;104:235–41. 10.1097/00000542-200602000-00006
    1. Combes A, Figliolini C, Trouillet J-L, et al. . Incidence and outcome of polymicrobial ventilator-associated pneumonia. Chest 2002;121:1618–23. 10.1378/chest.121.5.1618
    1. Luyt C-E, Guérin V, Combes A, et al. . Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005;171:48–53. 10.1164/rccm.200406-746OC
    1. Ling ML, Apisarnthanarak A, Madriaga G. The burden of healthcare-associated infections in Southeast Asia: a systematic literature review and meta-analysis. Clin Infect Dis 2015;60:1690–9. 10.1093/cid/civ095
    1. Siempos II, Athanassa Z, Falagas ME. Frequency and predictors of ventilator-associated pneumonia recurrence: a meta-analysis. Shock 2008;30:487–95. 10.1097/SHK.0b013e31816f1f7c
    1. Chastre J, Wolff M, Fagon J-Y, et al. . Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588–98. 10.1001/jama.290.19.2588
    1. Center for Biologics Evaluation and Research (CBER) C for DE and R (CDER) . Guidance for industry non-inferiority clinical trials, 2010. Available:
    1. Rothmann MD, Wiens BL, Chan ISF. Design and analysis of non-inferiority trials. Amsterdam: Chapman and Hall/CRC, 2011: 454.
    1. Durrleman S, Simon R. Planning and monitoring of equivalence studies. Biometrics 1990;46:329. 10.2307/2531438
    1. ELSEVIER . MACRO electronic data capture, 2019. Available:
    1. Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. London: Chapman & Hall/CRC, 2000: 390.
    1. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977;64:191–9. 10.1093/biomet/64.2.191
    1. Stolz D, Smyrnios N, Eggimann P, et al. . Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009;34:1364–75. 10.1183/09031936.00053209
    1. Berton DC, Kalil AC, Teixeira PJZ. Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. Cochrane Database Syst Rev 2014;10:CD006482. 10.1002/14651858.CD006482.pub4
    1. Eldridge SM, Chan CL, Campbell MJ. CONSORT 2010 statement : extension to randomised pilot and feasibility trials The Consolidated Standards of Reporting Trials (CONSORT) statement reporting of randomised controlled an extension to that statement for. BMJ Br Med J 2010;2016:1–29.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅